BIOBV.HE
Price:
$2.74
Market Cap:
$42.09M
Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; ...[Read more]
Industry
Biotechnology
IPO Date
2000-01-03
Stock Exchange
HEL
Ticker
BIOBV.HE
According to Biohit Oyj’s latest financial reports and current stock price. The company's current PE Ratio is 16.12. This represents a change of 97.37% compared to the average of 8.17 of the last 4 quarters.
The mean historical PE Ratio of Biohit Oyj over the last ten years is -6.31. The current 16.12 PE Ratio has changed -25666.29% with respect to the historical average. Over the past ten years (40 quarters), BIOBV.HE's PE Ratio was at its highest in in the June 2010 quarter at 41.40. The PE Ratio was at its lowest in in the December 2005 quarter at -61.54.
Average
-6.31
Median
-14.84
Minimum
-35.61
Maximum
39.30
Discovering the peaks and valleys of Biohit Oyj PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 68.99%
Maximum Annual PE Ratio = 39.30
Minimum Annual Increase = -328.15%
Minimum Annual PE Ratio = -35.61
Year | PE Ratio | Change |
---|---|---|
2024 | 13.35 | -15.61% |
2023 | 15.82 | -59.74% |
2022 | 39.30 | -313.54% |
2021 | -18.41 | 63.37% |
2020 | -11.27 | -68.36% |
2019 | -35.61 | 68.99% |
2018 | -21.07 | -328.15% |
2017 | 9.24 | -134.25% |
2016 | -26.96 | -1.80% |
2015 | -27.46 | -49.97% |
The current PE Ratio of Biohit Oyj (BIOBV.HE) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
22.83
5-year avg
7.76
10-year avg
-6.31
Biohit Oyj’s PE Ratio is less than Bittium Oyj (32.79), greater than Dovre Group Plc (-3.40), greater than Afarak Group Oyj (-358.57), greater than Tecnotree Oyj (6.67), greater than SSH Communications Security Oyj (-13.79),
Company | PE Ratio | Market cap |
---|---|---|
32.79 | $243.79M | |
-3.40 | $27.06M | |
-358.57 | $76.21M | |
6.67 | $52.01M | |
-13.79 | $44.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biohit Oyj using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biohit Oyj or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Biohit Oyj's PE Ratio?
How is the PE Ratio calculated for Biohit Oyj (BIOBV.HE)?
What is the highest PE Ratio for Biohit Oyj (BIOBV.HE)?
What is the 3-year average PE Ratio for Biohit Oyj (BIOBV.HE)?
What is the 5-year average PE Ratio for Biohit Oyj (BIOBV.HE)?
How does the current PE Ratio for Biohit Oyj (BIOBV.HE) compare to its historical average?